Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read why MTSR stock is a Strong Buy.

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside.

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...

In other recent news, Metsera Inc has garnered significant attention with its initial public offering (IPO) debut on the Nasdaq Global Select Market, opening 42% higher than its initial offering ...

Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...